Jun

2010

Predictive Biosciences, Inc.: Series C $25M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Device (Diagnostic), X - Oncology, XX - MA

Predictive Biosciences (Lexington, MA) a commercial-stage molecular diagnostic company focused on oncology assays, closed a $25M Series C financing. Participants ProQuest Investments, Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

Jun

2010

Anulex Technologies, Inc.: Series E $18.3M

Posted in I - Series E, Q - 2Q10, R - MID WEST, X - Device (Spine), XX - MN

Anulex Technologies (Minnetonka, MN) a commercial-stage medical device company focused on herniated discectomy procedures, closed a $18.3M Series E financing. Participants include Hatteras Late Stage VC Fund, Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.

May

2010

Tesaro, Inc.: Series A $60M

Posted in I - Series A, Q - 2Q10, R - NORTH EAST, X - Oncology, XX - MA

Tesaro (Boston, MA) a preclinical-stage biopharmaceutical company focused on oncology therapeutics, closed a $60M Series A financing. Participants include New Enterprise Associates.

Apr

2010

Liquidia Technologies, Inc.: Series C $13M

Posted in I - Series C, Q - 1Q10, R - SOUTH EAST, X - Device (Delivery), X - Vaccines, XX - NC

Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $13M Series C financing, bringing the total round to $20M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside and Firelake Capital.

Mar

2010

Carticept, Inc.: Series B $20M

Posted in I - Series B, Q - 1Q10, R - SOUTH EAST, X - Device (Delivery), XX - GA

Carticept (Alpharetta, GA) a near commercial-stage medical device company focused on a computer controlled infusion system for osteoarthritis and cartilage injuries, closed a $20M Series B financing. Participants include SonoSite, Domain Associates and New Enterprise Associates.

Mar

2010

Rhythm Pharmaceuticals, Inc.: Series A $10M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Diabetes, X - GI, X - Metabolism, X - Obesity, XX - MA

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage biopharmaceutical company whose peptide therapeutic agonists are focused on metabolic disorders, closed a $10M Series A financing. Participants include MPM Capital and New Enterprise Associates.

Feb

2010

PhaseBio Pharmaceuticals, Inc.: Series B $25M

Posted in I - Series B, Q - 1Q10, R - SOUTH EAST, X - Biologics Mfg., XX - NC

PhaseBio Pharmaceuticals (Research Triangle Park, NC) a development-stage biopharma company focused on elastin-like fusion proteins for improved expression and purification of biological, closed a $25M Series B financing. Participants include New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Development Corp. and Fletcher Spaght Ventures.

Feb

2010

Apnex Medical, Inc.: Series B $14M

Posted in I - Series B, Q - 4Q09, R - MID WEST, X - Device (Sleep Apnea), XX - MN

Apnex Medical (St. Paul, MN) a clinical-stage medical device company developing an implantable treatment for moderate-to-severe obstructive sleep apnea, closed a $14M Series B financing. Participants include Domain Associates, New Enterprise Associates and Polaris Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Feb

2010

Epizyme, Inc.: Series B $8M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]

Feb

2010

Zyngenia, Inc.: Series A $10M

Posted in I - Series A, Q - 4Q09, R - MID ATLANTIC, X - Antibody, X - Autoimmune, X - Oncology, X - Therapeutic Platform, XX - MD

Zyngenia (Rockville, MD) a pre-clinical stage biotherapeutics company focused on multi-specific antibodies for oncology and autoimmune disorders, closed a $10M Series A financing. Particpants include New Enterprise Associates.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

TriVascular, Inc.: Series B $30M

Posted in I - Series B, Q - 4Q09, R - WEST, X - Device (Stent), X – Device (Aneurysm), XX - CA

TriVascular (Santa Rosa, CA) a clinical-stage medical device company focused on transluminally placed endovascular stent grafts for abdominal and thoracic aortic disease, closed a $30M Series B financing. Participants include New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Next Entries »

to top of page...